An Elsevier Indexed Journal ISSN-2230-7346

Journal of Global Trends in Pharmaceutical Sciences

EXPLORING STABILITY TESTING GUIDELINES FOR NEW DRUG SUBSTANCES: AN INSIGHT INTO ICH RECOMMENDATIONS

Gireesh Kumar Eri[1,2]*, Chakka Gopinath[3], S.V. Satyanarayana[4]

[1] Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, 515002, India.
[2]Department of Pharmaceutical Analysis, Annamacharya College of Pharmacy, Rajampet, 516126, India.
[3]Oil Technological & Pharmacy Research Institute, JNTUA, Ananthapuramu, 515002, India.
[4]Department of Chemical Engineering, JNTUA College of Engineering, Ananthapuramu, 515002, India.

*Corresponding author E-mail: gireeshpharma@gmail.com

ARTICLE INFO

Key Words
Stability testing;
Stress testing;
ICH Q1A;
drug substance;
drug product

ABSTRACT

Stability testing of new drug substances or products is crucial for regulatory approval. This intricate process ensures the quality, efficacy, and safety of drug substances and products. The primary objective of stability testing is to demonstrate how a drug's quality changes over time under various environmental conditions, such as temperature, humidity, and light. This information helps establish the re-test period for drug substances and the shelf life and recommended storage conditions for drug products. Stress testing, conducted under more extreme conditions than accelerated testing, is part of the development strategy and helps determine the intrinsic stability of the drug substance. This review focuses on the stability testing of new drug substances according to ICH Q1A(R2) guidelines, which outline the necessary information for registration applications for new molecular entities and their related drug products.

INTRODUCTION

A drug substance is the active ingredient that can be combined with excipients to create the dosage form, while the drug product is the final dosage form in its immediate packaging for marketing. Dosage forms include pharmaceutical product types such as tablets, capsules, solutions, and creams, which generally contain a drug substance along with excipients. Stability refers to a substance's ability to maintain its original properties and characteristics throughout its storage and use period, within specified limits.

Stability testing of new drug substances or products is crucial for regulatory approval, ensuring quality, efficacy, and safety. This process requires significant investment in time, costs, and technical expertise. Therefore, during development, stability studies are essential to verify and ensure the purity of both drug substances and products. The primary goal of stability testing is to provide evidence on how a drug substance's quality changes over time due to environmental factors like temperature, humidity, and light. This helps establish the re-test period for drug substances and the shelf life and storage conditions for drug products[1].

However, stability testing is complex due to various factors influencing the stability of a drug substance or product. These factors include the stability of the drug substance(s), interactions between the drug substance and excipients, the manufacturing process, the dosage form type, the container/closure system, and conditions such as heat, light, and moisture encountered during

transport, storage, and handling. Furthermore, degradation reactions can significantly impact the stability of a drug substance or product. Fig. 1 illustrates the factors influencing the stability and the effects of instability on drug products. As a result, a drug product may undergo changes in appearance, particle size and shape, consistency, clarity (if it is a solution), moisture content, pH, content uniformity, and package integrity, affecting its stability. These changes can result from abrasion, impact, vibration, and temperature fluctuations. Chemical reactions within the drug substance or product can lead to degradation product formation, potency loss, and excipient activity loss[2]. Additionally, microbial growth in non-sterile products and changes in preservative efficacy can also affect drug substance stability[3].

To address these challenges, regulatory authorities worldwide have established regulations requiring the submission of stability data for drug substances and products. These regulations aim to standardize stability testing, with guidelines covering fundamental stability issues, data requirements, and implementation steps[4]. Initially issued in the 1980s, these guidelines were later harmonized by the ICH to facilitate product registration in multiple countries. This harmonization ensures a uniform approach to stability testing, enhancing the reliability and consistency of stability data submitted for regulatory approval.

Table 1: ICH Guidelines on stability testing.

Code	Title
Q1A	Stability testing of New Drug Substances and Products
Q1B	Stability testing: Photostability testing of New Drug Substances and Products
Q1C	Stability testing of New Dosage Forms
Q1D	Bracketing and Matrixing Designs for stability testing of Drug Substances and Products
Q1E	Evaluation of stability data
Q1F	Stability data package for Registration Applications in Climatic Zones III and IV
Q5C	Quality of Biotechnological Products: Stability testing of Biotechnological/ Biological Products

ICH GUIDELINES ON STABILITY TESTING:

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) unites regulatory authorities and the pharmaceutical industry to develop guidelines for pharmaceutical registration. Its primary objective is to promote public health through international harmonisation, preventing unnecessary duplication of clinical trials and post-market evaluations, supporting new medicine development and manufacturing, and ensuring proper registration and supervision. Additionally, ICH seeks to reduce unnecessary animal testing while maintaining safety and effectiveness.



Fig. 1. Factors influencing the stability and the effects of instability on drug products.

This is achieved through Technical Guidelines implemented by regulatory authorities. Notable achievements in quality include stability studies, setting impurity testing thresholds, and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management[5]. The harmonisation efforts by ICH in stability testing have led to significant advancements in the quality management of pharmaceuticals. They have helped streamline the process of drug development and registration, reduced unnecessary duplication of studies, and ensured that stability testing practices are consistent across different regulatory regions. ICH Guidelines on Stability testing have been outlined in the Table 1. These guidelines ensure that pharmaceutical products meet international standards for quality, safety, and efficacy.

TYPES OF STABILITY STUDIES:

Formal Stability Studies: These encompass long-term, accelerated, and intermediate stability studies conducted on primary and/or commitment batches according to a prescribed protocol. A comparative summary for stability testing protocols for different dosage forms represented in Table 2. Their purpose is to establish or confirm the re-test period of a drug substance or the shelf life of a drug product.

Long-Term Testing: Stability studies performed under recommended storage conditions for the proposed (or approved) re-test period or shelf life indicated on the labeling.

Intermediate Testing: Stability studies conducted at 30°C/65% RH, designed to moderately accelerate chemical degradation or physical changes in a drug substance or product intended for long-term storage at 25°C.

Accelerated Testing: Stability studies that use exaggerated storage conditions to hasten chemical degradation or physical changes in a drug substance or product. These are part of formal stability studies and provide data, along with long-term studies, to assess long-term chemical effects under normal storage conditions and evaluate the impact of short-term deviations from labeled storage conditions, such as during shipping. However, results from accelerated testing are not always predictive of physical changes.

Stress Testing: These studies determine the intrinsic stability of a drug substance by subjecting it to more severe conditions than those used in accelerated testing. Stress testing is part of the development strategy.

STABILITY TESTING OF NEW DRUG SUBSTANCES

The ICH Q1A(R2) guidelines provide comprehensive directives for the stability testing of new drug substances and products[6]. These guidelines define the stability data package necessary for the registration application in the EC, Japan, and the United States. They aim to illustrate the core stability data requirements while offering flexibility to accommodate various practical scenarios influenced by specific scientific considerations and material characteristics. Scientifically justifiable alternative approaches are permitted. The guidelines offer detailed recommendations on stability testing protocols, including specified conditions for temperature, humidity, and trial duration for Climatic Zones I and II. The revised Q1A(R2) guidelines also consider the stability testing requirements for Climatic Zones III and IV, aiming to harmonize storage conditions for global submissions. The ICH Q1A(R2) guideline outlines the information required for registration applications of new molecular entities and associated drug products. However, it does not cover the requirements for abbreviated or abridged applications, variations, or clinical trial applications. Additionally, it does not detail sampling and testing protocols for specific dosage forms within their proposed container closures. The test conditions specified in ICH Q1A(R2) are based on an analysis of climatic effects in the EC, Japan, and the United States. The global mean kinetic temperature can be derived from climatic data, dividing the world into four climatic zones (I-IV) (Table 3). ICH Q1A(R2) addresses Zones I and II. Stability information generated in any one of the three regions is considered mutually acceptable to the others, provided it aligns with the guidelines and labeling requirements specific to each region.

Table 2. Comparative table for Stability Testing Protocols during Product Development

Doc. No. / Heading	Solid Oral Dosage Forms (Tablets)	Liquid Dosage Forms (Solutions / Syrups / Suspensions)	Semi-Solid Dosage Forms (Ointments)
Document Control	Protocol title, number, version, product name, strength, batch numbers, blister/bottle pack details	Protocol title, number, version, product name, strength, bottle/ampoule type, closure system	Protocol title, number, version, product name, strength, tube/jar type, closure
Purpose	To establish shelf-life, storage conditions, and packaging suitability of tablets during development	To assess physical, chemical, and microbiological stability of liquid formulations	To evaluate physical, chemical, rheological, and microbiological stability of ointments
Scope	Applies to development, pilot, and scale-up batches of tablets	Applies to preserved/unpreserved liquid dosage forms	Applies to ointments intended for topical application
References	ICH Q1A(R2), Q1B, Q1E; IP/USP; in-house specs	ICH Q1A(R2), Q1B, Q1E; IP/USP; microbial guidelines	ICH Q1A(R2), Q1B, Q1E; IP/USP; topical product guidelines
Responsibilities	R&D (sample placement), QC (testing), QA (review, approval), Engineering (chambers)	R&D, QC (chemical + microbial), QA, Engineering	R&D, QC (physical + chemical + microbial), QA
Batch Selection	Minimum 3 representative batches (2 pilot + 1 scale-up preferred)	Minimum 3 batches including preservative system	Minimum 3 batches with final composition
Packaging System	Alu-Alu / PVC-PVDC blisters, HDPE bottle with desiccant	Amber PET/HDPE bottles, glass bottles, ampoules	Aluminum/laminated tubes, HDPE jars
Storage Conditions	Long-term: 30°C/75% RHAccelerated: 40°C/75% RH	Long-term: 30°C/75% RHAccelerated: 40°C/75% RHAdditional: 5°C (precipitation risk)	Long-term: 30°C/75% RHAccelerated: 40°C/75% RHAdditional: 5°C, high-temp stress
Study Duration & Pull Points	Accel: 0,1,2,3,6 monthsLT: 0,3,6,9,12 months	Accel: 0,1,2,3,6 monthsLT: 0,3,6,9,12 months	Accel: 0,1,2,3,6 monthsLT: 0,3,6,9,12 months
Physical Tests	Appearance, hardness, friability, thickness, disintegration, moisture	Appearance, clarity, color, pH, viscosity, sedimentation (suspensions)	Appearance, homogeneity, phase separation, spreadability, extrudability
Chemical Tests	Assay, related substances, dissolution, content uniformity	Assay, related substances, preservative content, antioxidant content	Assay, related substances, pH (if applicable), preservative content
Microbiological Tests	Usually not required (unless special products)	Microbial limits, preservative efficacy test, in-use study	Microbial limits, preservative efficacy test
Data Evaluation & Reporting	Trend analysis for assay, impurities, dissolution; shelf-life estimation as per ICH Q1E	Trend analysis for assay, pH, viscosity, microbial results; shelf-life assignment	Trend analysis for viscosity, assay, phase stability; shelf-life assignment

Table 3. Climatic Zones and Testing Conditions

Climatic Zone	Long Term Testing	
	Temperature °C	Relative Humidity % RH
I	21	45
II	25	60
III	30	35
IV a	30	65
IVb	30	75

Stress Testing:

Stress testing of the drug substance can help to predict the possible degradation products, which can in turn help to establish the degradation pathways and the intrinsic stability of the molecule and validate the stability indicating nature of the analytical methods used. The nature of the stress testing will depend on the individual drug substance and the type of drug product involved. Stress conditions used for degradation of drug substance were depicted in Fig. 2. Stress testing is likely to be carried out on a single batch of the drug substance. It should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.) above that for accelerated testing), humidity (e.g., 75% RH or greater), oxidation, and photolysis on the drug substance. The testing should

also assess the susceptibility of the drug substance to hydrolysis across a wide range of pH values when in solution or suspension. Photostability testing should be an integral part of stress testing.

Selection of Batches: The selection of batches for stability studies should involve a random sample from the pilot or production scale population. Data from formal stability studies should be provided for at least three primary batches of the drug substance. These batches must be manufactured to at least pilot scale, using the same synthetic route and a method that simulates the final production process. The overall quality of the batches subjected to formal stability studies should be representative of the quality expected in full-scale production.



Fig.2. Stress conditions used for degradation studies

Container Closure System: Stability studies should be conducted on the drug substance packaged in a container closure system that either matches or simulates the proposed packaging for storage and distribution.

Specification: Specifications, as outlined in ICH Q6A7, encompass a list of tests (both universal and specific), references to analytical procedures, and proposed acceptance criteria.[7].

Universal Tests: Table 4 details the tests generally applicable to all new drug substances.

Specific Tests: Table 5 outlines tests that may be considered on a case-by-case basis for drug substances. These tests should be included in the specifications when they impact the quality of the drug substance and drug product for batch control. Additional tests not listed may be required in specific situations or as new information emerges.

Furthermore, any degradation product observed in stability studies at recommended storage conditions exceeding the identification threshold should be identified. If identifying an impurity is not feasible, a summary of the laboratory studies demonstrating the unsuccessful effort should be included in the application. Additionally, results from attempts to identify impurities present at levels below the identification thresholds should also be reported.

Table 4. Universal Tests

Name of the test	Description
Description	A descriptive statement regarding the physical state (e.g., liquid, solid) and color of the novel drug substance.
Identification	Identification testing should ideally possess the capability to distinguish between compounds with closely related structures that are expected to be present. In the case of a new drug substance being a salt, the identification testing should be tailored to the individual ions. A test that specifically targets the salt should be adequate. Additionally, new drug substances exhibiting optical activity may require specific identification testing or the execution of a chiral assay.
Assay	A dedicated stability-indicating procedure should be incorporated to assess the content of the new drug substance. Frequently, it is feasible to utilize the same procedure for both determining the assay of the new drug substance and quantifying impurities.
Impurities	This category encompasses both organic and inorganic impurities, as well as residual solvents.

Stability studies should include testing attributes of the drug substance that are susceptible to change during storage and likely to influence quality, safety, and/or efficacy. These studies should appropriately cover physical, chemical, biological, and microbiological attributes. Validated stability-indicating analytical procedures should be applied. The necessity and extent of replication will depend on the results from validation studies.

Testing Frequency: For long-term studies, testing frequency should be sufficient to establish the stability profile of the drug substance. For drug substances with a proposed re-test period of at least 12 months, testing at long-term storage conditions should typically occur every 3 months during the first year, every 6 months during the second year, and annually thereafter throughout the proposed re-test period. At the accelerated storage condition, a minimum of three time points, including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-month study is recommended. If there is an expectation based on development experience that results from accelerated studies may approach significant change criteria, increased testing should be conducted either by adding samples at the final time point or by including a fourth time point in the study design. When testing at the intermediate storage condition is required due to significant change at the accelerated storage condition, a minimum of four time points, including the initial and final time points (e.g., 0, 6, 9, 12 months), from a 12-month study is recommended.

Storage Conditions: The intended label storage conditions specified by ICH guidelines are detailed in Table 6. In general, a comprehensive evaluation of a drug substance should be assessed under storage conditions (with appropriate tolerances) that assess both its thermal stability and, if applicable, its sensitivity to moisture. These conditions, along with the duration of studies chosen, should adequately cover storage, shipment, and subsequent use.

Long-term testing should extend over a minimum duration of 12 months, involving at least three primary batches at the time of submission and continuing for a period sufficient to encompass the proposed re-test period. Additional data gathered during the registration application assessment period should be provided to regulatory authorities upon request. Information from accelerated and, if applicable, intermediate storage conditions can be utilized to assess the impact of short-term deviations from labeled storage conditions, such as those occurring during shipping. If long-term studies are conducted at 25°C ± 2°C/60% RH ± 5% RH and a "significant change" is observed at any point during the 6-month testing period at the accelerated storage condition, further testing at the intermediate storage condition should be undertaken and assessed against significant change criteria. Testing at the intermediate storage condition should encompass all tests, unless there are specific justifications otherwise. The initial application should include at least 6 months' worth of data from a 12-month study conducted at the intermediate storage condition. "Significant change" in the context of a drug substance is defined as the failure to meet its specification.

Data obtained from refrigerated storage should be evaluated in accordance with the assessment criteria outlined in the evaluation section of the ICH Q1A(R2) guideline, unless stated otherwise. If a significant change is observed between 3 and 6 months of testing at the accelerated storage condition, the proposed re-test period should be determined based on the real-time data obtained from the long-term storage condition. In cases where a significant change occurs within the initial 3 months of testing at the accelerated storage condition, a discussion should be provided to address the impact of short-term deviations from the labeled storage condition, such as those encountered during shipping or handling. This discussion may be supplemented, if necessary, by additional testing on a single batch of the drug substance for a period shorter than 3 months, but with more frequent testing than usual. It is deemed unnecessary to continue testing a drug substance for the full 6-month duration if a significant change has already been observed within the initial 3 months. For drug substances intended for freezer storage, the re-test period should be determined based on real-time data obtained from the long-term storage condition. In the absence of an accelerated storage condition for drug substances designated for freezer storage, testing on a single batch at an elevated temperature (e.g., 5°C ± 3°C or 25°C ± 2°C) for an appropriate duration should be conducted to evaluate the impact of short-term deviations from the recommended label storage condition, such as those occurring during shipping or handling. Drug substances intended for storage below -20°C should be assessed on a case-by-case basis.

Table 5. Specific Tests considered for drug substances

Name of the test	Description
Physicochemical properties	These are properties such as pH of an aqueous solution, melting point / range, and refractive index.
Particle size	Testing for particle size distribution should be carried out using an appropriate procedure for some new drug substances intended for use in solid or suspension drug products, particle size can have a significant effect on dissolution rates, bioavailability, and / or stability.
Polymorphic forms	Some new drug substances exist in different crystalline forms which differ in their physical properties. Polymorphism may also include solvation or hydration products (also known as pseudopolymorphs) and amorphous forms. Differences in these forms could, in some cases, affect the quality or performance of the new drug products. In cases where differences exist which have been shown to affect drug product performance, bioavailability or stability, then the appropriate solid state should be specified. Physicochemical measurements and techniques are commonly used to determine whether multiple forms exist.
Tests for chiral new drug substances	Where a new drug substance is predominantly one enantiomer, the opposite enantiomer is excluded from the qualification and identification thresholds given in the ICH Q3A, Q3B Guidelines because of practical difficulties in quantifying it at those levels.
Water content	This test is important in cases where the new drug substance is known to be hygroscopic or degraded by moisture or when the drug substance is known to be a stoichiometric hydrate. In some cases, a Loss on Drying procedure may be considered adequate; however, a detection procedure that is specific for water (e.g., Karl Fischer titration) is preferred.
Inorganic impurities	The need for inclusion of tests and acceptance criteria for inorganic impurities (e.g., catalysts) should be studied during development and based on knowledge of the manufacturing process. Procedures and acceptance criteria for sulfated ash / residue on ignition should follow pharmacopoeial precedents; other inorganic impurities may be determined by other appropriate procedures
Microbial limits	The total count of aerobic micro-organisms, the total count of yeasts and molds, and the absence of specific objectionable bacteria (e.g., *Staphylococcus aureus*, *Escherichia coli*, *Salmonella*, *Pseudomonas aeruginosa*) should be suitably determined using pharmacopoeial procedures. The type of microbial test(s) and acceptance criteria should be based on the nature of the drug substance, method of manufacture, and the intended use of the drug product.

Table 6. Storage Conditions of Stability studies

Intended Storage Condition	Type of Study	Storage condition		Minimum time period
		Temperature	Relative Humidity	
Room Temperature (in general)	Long term[#]	25 ± 2°C	60% ± 5% RH	12 months
			OR	
		30 ± 2°C	65% ± 5% RH	
	Intermediate[$]	30 ± 2°C	65% ± 5% RH	6 months
	Accelerated	40 ± 2°C	75% ± 5% RH	6 months
Refrigerator	Long term	5 ± 3°C		12 months
	Accelerated	25 ± 2°C	60% ± 5% RH	6 months
Freezer	Long term	- 20°C ± 5°C		12 months

#The decision to conduct long-term stability studies at either 25 ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH is left to the discretion of the applicant.

$ If the chosen long-term condition is 30°C ± 2°C/65% RH ± 5% RH, an intermediate condition is not required.

Stability Commitment: If long-term stability data from primary batches do not encompass the proposed re-test period granted upon approval, a commitment should be made to continue stability studies post-approval to definitively establish the re-test period. If the submission includes long-term stability data from three production batches covering the proposed re-test period, a post-approval commitment is deemed unnecessary. Otherwise, one of the following commitments should be made:

"If the submission includes stability data from at least three production batches, a commitment should be made to extend these studies through the proposed re-test period."

"If the submission includes stability data from fewer than three production batches, a commitment should be made to extend these studies through the proposed re-test period and to include additional production batches, totaling at least three, in long-term stability studies through the proposed re-test period."

"If the submission lacks stability data from production batches, a commitment should be made to subject the initial three production batches to long-term stability studies through the proposed re-test period."

The stability protocol utilized for long-term studies in the stability commitment should mirror that of the primary batches, unless scientifically justified otherwise.

Evaluation: The aim of the stability study is to determine, by testing at least three batches of the drug substance and assessing stability information (including results from physical, chemical, biological, and microbiological tests), a re-test period applicable to all subsequent batches of the drug substance manufactured under comparable conditions. The level of variability among individual batches impacts the certainty that a future production batch will remain within specification throughout the designated re-test period. If the data indicate minimal degradation and variability to the extent that it is evident from the data that the requested re-test period will likely be approved, formal statistical analysis is typically unnecessary under such circumstances. In these cases, providing a justification for omitting the analysis should suffice. An approach to analyze data on a quantitative attribute expected to change over time is to identify the time at which the 95% one-sided confidence limit for the mean curve intersects the acceptance criterion. If the analysis indicates minimal batch-to-batch variability, consolidating the data into a single overall estimate is beneficial. This can be achieved by initially subjecting the slopes of the regression lines and zero time intercepts for individual batches to appropriate statistical tests (e.g., p-values for significance level exceeding 0.25). If combining data from multiple batches is deemed inappropriate, the overall re-test period should be determined based on the shortest duration a batch is anticipated to meet the acceptance criteria. Whether the data should undergo transformation for linear regression analysis depends on the nature of the degradation relationship. Typically, the relationship can be described by a linear, quadratic, or cubic function on either an arithmetic or logarithmic scale. Statistical methods should be utilized to assess the goodness of fit of the data from all batches, as well as combined batches where applicable, to the assumed degradation line or curve.

Limited extrapolation of real-time data from long-term storage conditions beyond the observed range to extend the re-test period can be considered at the time of approval, provided it is justified. The justification should be based on knowledge of the degradation mechanism, results from testing under accelerated conditions, the goodness of fit of any mathematical model, batch size, and the existence of supporting stability data, among other factors. This extrapolation assumes that the same degradation relationship will persist beyond the observed data. The evaluation should encompass not only the assay but also the levels of degradation products and other relevant attributes.

Statements/Labeling: A storage statement should be established for labeling in accordance with relevant national and regional requirements. This statement should be based on the stability evaluation of the drug substance. Where applicable, specific instructions should be provided, especially for drug substances that cannot tolerate freezing. Terms such as "ambient conditions" or "room temperature" should be avoided. A re-test period should be derived from the stability information, and if appropriate, a re-test date should be displayed on the container label.

PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCE (ICH Q1B)

Photostability testing[9] for drug substances comprises two parts: forced degradation testing and confirmatory testing.

Forced Degradation Testing

The purpose of forced degradation testing is to evaluate the overall photosensitivity of the material, aiding method development and degradation pathway elucidation. This testing may involve the drug substance alone or in

simple solutions/suspensions to validate analytical procedures. Samples should be contained in chemically inert and transparent containers. Various exposure conditions may be employed, depending on the drug substance's photosensitivity and the light sources' intensity. For photostable materials, studies can be concluded after reaching an appropriate exposure level. The design and exposure levels of these experiments are at the applicant's discretion but must be justified. Under forcing conditions, decomposition products may be observed that are unlikely to form under confirmatory study conditions. Such information is useful for developing and validating analytical methods. If these degradation products are not formed in confirmatory studies, they need not be further examined.

Confirmatory Testing

Confirmatory studies are conducted to provide the necessary information for handling, packaging, and labeling the drug substance. Typically, only one batch is tested during development, confirming photostability characteristics if the drug is clearly photostable or photolabile. If results are equivocal, testing of up to two additional batches should be conducted. Sample selection should follow the discussion provided earlier in this manuscript.

Presentation of Samples: Care should be taken to account for the physical characteristics of the samples under test. Efforts should be made, such as cooling and/or placing the samples in sealed containers, to minimize the effects of changes in physical states such as sublimation, evaporation, or melting. These precautions should interfere minimally with the exposure of samples under test. Possible interactions between the samples and any material used for containers or general protection should be considered and eliminated if they are not relevant to the test.

For solid drug substances, an appropriate amount of sample should be taken and placed in a suitable glass or plastic dish, protected with a suitable transparent cover if necessary. Solid drug substances should be spread across the container to a thickness typically not more than 3 millimeters. Liquid drug substances should be exposed in chemically inert and transparent containers.

Judgement of Results: Forced degradation studies should be designed to provide suitable information for developing and validating test methods for confirmatory studies. These test methods should be capable of resolving and detecting photolytic degradants that appear during the confirmatory studies. It is important to recognize that forced degradation studies are part of stress testing and are not intended to establish qualitative or quantitative limits for change. Confirmatory studies should identify precautionary measures needed in manufacturing or formulation of the drug product and determine if light-resistant packaging is necessary. When evaluating the results of confirmatory studies, it is important to consider other formal stability studies to ensure the drug remains within justified limits at the time of use.

Examining degradation products under stress conditions is useful for establishing degradation pathways and developing and validating suitable analytical procedures. However, it may not be necessary to examine specifically for certain degradation products if it has been demonstrated that they are not formed under accelerated or long-term storage conditions. Results from these studies will form an integral part of the information provided to regulatory authorities.

STABILITY TEST EQUIPMENT

The equipment used for stability testing, known as stability chambers, are specialized environmental chambers designed to simulate storage conditions and enable the evaluation of product stability based on real-time, accelerated, and long-term protocols. Stability chambers are available in both walk-in and reach-in styles. Smaller reach-in chambers are preferred for accelerated testing due to their shorter product withholding times, while walk-in chambers are ideal for long-term testing. These chambers are engineered and qualified to ensure uniform exposure of set conditions to all samples within the chamber. They are designed to be dependable and robust, capable of uninterrupted use over several years, and are equipped with appropriate recording, safety, and alarm devices.

Additionally, photostability chambers are available and used both with and without temperature and humidity control. These chambers employ two types of light sources: a combination of cool white and near UV fluorescent tubes, and artificial daylight lamps, such as xenon or metal halide. The required total exposure is 1.2 million lux hours, with the visible light intensity measured using a lux meter to calculate the necessary hours of exposure.

IMPORTANCE OF STABILITY TESTING

The primary reason for stability testing is to ensure patient safety, particularly for those suffering from diseases for which the pharmaceuticals are designed. Unstable drug substances can degrade into toxic decomposition products, and the loss of the drug's claimed activity on the label can lead to therapeutic failure, potentially resulting in severe consequences, including death. Regulatory agencies, therefore, mandate stability testing data for drug approval. Stability testing also protects the manufacturer's reputation by ensuring that the product remains fit for use with respect to all functionally relevant attributes throughout its market life. Additional benefits of stability studies at both the developmental stage and for marketed products include:

(1) *Database Creation:* Provides valuable data for selecting adequate formulations, excipients, and container closure systems for new product development.

(2) *Shelf Life and Storage Conditions:* Helps determine the shelf life and appropriate storage conditions for new products.

(3) *Registration Dossier Preparation:* Aids in the preparation of the registration dossier and substantiates the claimed shelf life.

(4) *Verification of Formulation and Manufacturing:* Ensures that no changes in the formulation or manufacturing process adversely affect product stability.

CONCLUSION

Stability testing of new drug substance or drug product is an important requirement for regulatory approval. Stability tests are carried out to include the recommended storage conditions and shelf life on the label to ensure that the drug is safe and effective throughout the shelf life. The stringent regulatory requirements will be useful to achieve the above goal in all possible conditions to which the product might be subjected during its shelf life. Therefore, the stability tests should be carried out as per the current regulatory requirements and as per the climatic zone.

REFERENCES

1. Singh S., Bakshi M. Guidance on conduct of stress test to determine inherent stability of drugs. *Pharm Technol Asia,* Special Issue, Sep./Oct. 2000;24-36.
2. Carstensen JT. Drug Stability, Principles and Practices, *Marcel Dekker,* New York (2000)
3. Matthews RB. Regulatory Aspects of Stability Testing in Europe. *Drug Dev. Ind. Pharm.* 1999;25:831-856.
4. Sanjay Bajaj, Dinesh Singla and Neha Sakhuja, Stability Testing of Pharmaceutical Products, *J. Applied Pharm. Sci.* 02 (03); 2012: 129-138.
5. Overview of ICH, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. June 2020. https://admin.ich.org/sites/default/files/2019-11/OverviewOfICH_2019_1128.pdf
6. ICH Q1A(R2). Stability testing guidelines: Stability testing of new drug substances and products. ICH Steering Committee, 2003.
7. ICH Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, International Conference on Harmonisation of Technical requirements for registration of Pharmaceuticals for human use, Current Step 4 version, October 1999.
8. ICH Q3A(R2): Impurities in New Drug Substances, International Conference on Harmonisation of Technical requirements for registration of Pharmaceuticals for human use, Current Step 4 version, October 2006.
9. ICH Q1B. Guidance for Industry: Photostability testing of new drug substances and products. CDER, US FDA, 1996

***